targets
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets
Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson
Shrinking Budgets and Rising Targets Pile Pressure on Pharma Marketers: Survey Highlights 2025 Challenges
pharma marketing; shrinking budgets; rising targets; 2025 survey; healthcare marketing trends; budget constraints; innovation; marketing pressure
Antares Therapeutics Launches with $177M to Tackle ‘Undruggable’ Targets After Scorpion Spinout
Antares Therapeutics; Scorpion Therapeutics; biotech spinoff; $177M Series A; undruggable targets; oncology; precision medicine; Eli Lilly acquisition; preclinical pipeline
Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases
Novartis, BioAge Labs, Longevity, Exercise Biology, Age-Related Diseases, Therapeutic Targets, Human Longevity Data, Research Collaboration
GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments
Muna Therapeutics, GSK, Alzheimer’s disease, neurodegenerative diseases, spatial transcriptomics, MiND-MAP platform, drug discovery, therapeutic targets.
Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases
Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement